When should warfarin be initiated in patients with valvular heart disease after valve surgery (mechanical or bioprosthetic) or in those with native valve disease and atrial fibrillation?

When to Start Warfarin in Valvular Heart Disease Patients

Warfarin should be initiated within 24 hours after mechanical valve replacement surgery once postoperative bleeding stability is achieved, with bridging anticoagulation using intravenous unfractionated heparin started when the INR falls below 2.0. 1

Mechanical Valve Replacement

Immediate Postoperative Period

• Start warfarin within 24 hours of surgery as soon as hemostasis permits, regardless of valve position (aortic or mitral). 1
• Begin therapeutic-dose intravenous unfractionated heparin (UFH) when INR drops below 2.0, typically 48 hours after surgery if warfarin was held perioperatively, or immediately postoperatively if initiating anticoagulation de novo. 1
• Continue IV heparin until INR reaches therapeutic range on two consecutive measurements, then maintain both warfarin and heparin together for at least 24 hours with therapeutic INR before discontinuing heparin. 1
• Target aPTT of 60-80 seconds while on heparin bridge. 1

Target INR by Valve Position

Mechanical Mitral Valves:

• Target INR 2.5-3.5 (specifically targeting 3.0) for all mechanical valves in the mitral position, regardless of valve type (bileaflet, tilting disk, or caged ball/disk). 1, 2, 3
• The higher INR reflects the greater thromboembolic risk with mitral position valves (≈0.9%/year) compared to aortic valves (≈0.5%/year). 1

Mechanical Aortic Valves:

• For bileaflet mechanical valves (e.g., St. Jude Medical) in the aortic position: target INR 2.0-3.0 (targeting 2.5). 2, 3
• For tilting disk or caged ball/disk valves in the aortic position: target INR 2.5-3.5 (targeting 3.0). 2, 3

Adjunctive Antiplatelet Therapy

• Consider adding low-dose aspirin 75-100 mg daily to warfarin for additional thromboembolic protection, particularly in patients with additional risk factors (atrial fibrillation, prior thromboembolism, left ventricular dysfunction, or hypercoagulable state). 1, 2
• For caged ball or caged disk valves, aspirin 75-100 mg daily is recommended in combination with warfarin. 2, 3

Critical Timing Considerations

• Mechanical mitral valves carry extremely high thrombotic risk and can develop valve thrombosis within days of subtherapeutic anticoagulation. 1
• The first few days and months after valve insertion represent the highest embolic risk before the valve is fully endothelialized. 1
• Check INR daily during the acute postoperative phase and warfarin titration period. 1

Bioprosthetic Valve Replacement

Initial 3-6 Month Period

Bioprosthetic Mitral Valves:

• Warfarin is strongly recommended with INR target 2.5 (range 2.0-3.0) for the first 3 months (Grade 1A evidence). 4, 2, 3
• The 2020 ACC/AHA guidelines extend this to 3-6 months for patients at low bleeding risk. 4

Bioprosthetic Aortic Valves:

• Warfarin with INR target 2.5 (range 2.0-3.0) is reasonable for 3-6 months, though evidence is less compelling than for mitral valves (Grade 2C). 4, 2, 3
• A large Danish registry demonstrated lower stroke and mortality rates with 6 months of warfarin after bioprosthetic aortic valve replacement. 4

Bioprosthetic Tricuspid Valves:

• Warfarin INR 2.0-3.0 for 3-6 months after implantation is reasonable. 4

Bioprosthetic Pulmonary Valves:

• It is reasonable to forgo anticoagulation entirely. 4

Beyond 3-6 Months

• Continue warfarin indefinitely if atrial fibrillation is present (Grade 1C recommendation). 4, 2
• Continue warfarin if evidence of thrombus at surgery, though optimal duration is uncertain. 4
• Continue warfarin for 3-12 months if history of systemic embolism. 4
• For patients without these risk factors, switch to low-dose aspirin 75-100 mg daily after the initial 3-6 month period. 4, 3

DOAC Considerations After 3 Months

• DOACs may be used after the third postoperative month in patients with bioprosthetic valves and atrial fibrillation. 4
• DOACs are explicitly prohibited during the first three months after bioprosthetic valve implantation; warfarin remains the standard therapy in this high-risk period. 4
• The GALILEO trial showed harm with routine DOAC use, limiting their role. 4

Native Valve Disease with Atrial Fibrillation

Rheumatic Mitral Valve Disease

• Long-term warfarin with target INR 2.5 (range 2.0-3.0) is recommended for patients with rheumatic mitral valve disease and atrial fibrillation or history of systemic embolism (Grade 1C+). 3
• If systemic embolism occurs despite therapeutic INR, add aspirin 75-100 mg daily (Grade 1C). 3

Mitral Valve Prolapse

• No antithrombotic therapy is recommended for MVP without history of systemic embolism, unexplained TIAs, or atrial fibrillation (Grade 1C). 3
• For MVP with documented but unexplained TIAs, use long-term aspirin 50-162 mg daily (Grade 1A). 3

Other Valvular Disease with Atrial Fibrillation

• For AF with mitral stenosis, anticoagulation with warfarin is recommended (target INR 2.0-3.0). 2
• For AF with prosthetic heart valves, use warfarin; the target INR may be increased and aspirin added depending on valve type and position. 2

Perioperative Management (Non-Cardiac Surgery)

Stopping Warfarin

• Stop warfarin 3-4 days (or 2-4 days) before the procedure and restart postoperatively as soon as bleeding risk allows, typically 24 hours after surgery. 5
• Stop warfarin 5 days (five doses) prior to surgery when bridging therapy is planned. 5

Bridging Anticoagulation Strategy

High Thromboembolic Risk Patients (mechanical mitral valve, AVR with additional risk factors, multiple mechanical valves, recent valve surgery <3 months, or prior stroke/atrial fibrillation):

• Start LMWH or UFH 1 day after acenocoumarol interruption or 2 days after warfarin interruption when INR falls below therapeutic threshold (2.0 or 2.5), usually 36-48 hours before surgery. 5
• Stop IV UFH 4-6 hours before the procedure or stop subcutaneous LMWH 12 hours before the procedure. 5
• Use therapeutic-dose LMWH (70 U/kg twice daily) for high-risk patients. 5

Low Thromboembolic Risk Patients (bileaflet mechanical AVR with no other risk factors):

• Bridging anticoagulation can be avoided; the inconvenience and expense are unnecessary if warfarin is withheld for only a few days. 5

Emergency Surgery

• For emergency surgery requiring immediate reversal, administer intravenous 4-factor prothrombin complex concentrate (onset 5-15 minutes, duration 12-24 hours). 5
• The effect can be prolonged with vitamin K if indicated. 5

Common Pitfalls to Avoid

• Do not use large loading doses of warfarin; they increase hemorrhagic complications without offering more rapid protection. 2
• Do not apply the lower INR target (2.0-3.0) used for mechanical aortic valves to the mitral position; a higher intensity (2.5-3.5) is required. 1
• Do not assume that bileaflet mechanical mitral valves permit a lower INR; all mechanical mitral valves require the 2.5-3.5 range. 1
• Do not use DOACs routinely in bioprosthetic valves during the first 3 months; warfarin is the standard. 4
• Do not delay bridging beyond 48 hours after bleeding stops in high-risk patients; this interval balances thrombotic and hemorrhagic risks. 6
• The highest stroke risk occurs in the first 30-180 days after valve implantation (1.5% incidence within 30 days after bioprosthetic mitral valve replacement), justifying time-limited anticoagulation. 4